Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,441,872
  • Shares Outstanding, K 2,317,460
  • Annual Sales, $ 50,135 M
  • Annual Income, $ 7,703 M
  • 36-Month Beta 0.82
  • Price/Sales 3.88
  • Price/Cash Flow 10.90
  • Price/Book 2.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.35
  • Number of Estimates 2
  • High Estimate 1.38
  • Low Estimate 1.31
  • Prior Year 1.29
  • Growth Rate Est. (year over year) +4.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.09 +3.05%
on 08/15/18
84.50 -1.11%
on 07/31/18
+1.29 (+1.57%)
since 07/20/18
3-Month
72.30 +15.57%
on 06/28/18
84.50 -1.11%
on 07/31/18
+6.50 (+8.43%)
since 05/18/18
52-Week
72.30 +15.57%
on 06/28/18
94.19 -11.29%
on 01/26/18
+0.80 (+0.97%)
since 08/18/17

Most Recent Stories

More News
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose

Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.

BAYRY : 23.2900 (+2.46%)
NVS : 83.56 (+0.63%)
REGN : 374.80 (+0.14%)
SNY : 42.22 (+0.43%)
Amgen Stock Up This Year So Far: Will the Rally Continue?

After a relatively strong performance so far this year, let's see how things are poised for Amgen (AMGN) in the second half of the year.

AGN : 190.75 (+2.77%)
NVS : 83.56 (+0.63%)
RHHBY : 30.5350 (+1.38%)
AMGN : 197.56 (+0.07%)
Merck, Eisai Get FDA Approval for Lenvima Label Expansion

Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.

BAYRY : 23.2900 (+2.46%)
AZN : 38.85 (+1.92%)
MRK : 70.17 (+1.61%)
NVS : 83.56 (+0.63%)
Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

BAYRY : 23.2900 (+2.46%)
NVS : 83.56 (+0.63%)
REGN : 374.80 (+0.14%)
SNY : 42.22 (+0.43%)
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status

Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.

AIMT : 27.76 (-0.75%)
NVS : 83.56 (+0.63%)
RHHBY : 30.5350 (+1.38%)
SNY : 42.22 (+0.43%)
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

LLY : 105.82 (+0.26%)
NVS : 83.56 (+0.63%)
TEVA : 25.65 (+5.90%)
AMGN : 197.56 (+0.07%)
SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug

SOHM, Inc. (PINKSHEETS: SHMN), a globally-known generic pharmaceutical manufacturer, announced that its subsidiary Daiichi Sankyo Group filed its acute myeloid leukemia (AML) treatment Quizartinib in the...

SHMN : 0.0004 (-20.00%)
NVS : 83.56 (+0.63%)
Recommended Cash Offer for Vernalis plc

LNSTY : 14.2900 (-0.56%)
MRK : 70.17 (+1.61%)
BK : 51.94 (+0.48%)
BAX : 72.20 (+0.22%)
NVS : 83.56 (+0.63%)
VNLPF : 0.2190 (unch)
AMGN : 197.56 (+0.07%)
BIIB : 344.11 (-0.32%)
Corporate Reputation of Pharma Companies, 2017-2018: Patient Perspective of 262 Cancer Patient Groups - Janssen, Novartis, and Pfizer Dominate the Top Ranks

The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective of 262 Cancer Patient Groups - Cancer Edition" report has been added to ResearchAndMarkets.com's offering.

NVS : 83.56 (+0.63%)
Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View

Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.

SPPI : 23.14 (+1.58%)
LGND : 239.57 (-3.39%)
NVS : 83.56 (+0.63%)
AMGN : 197.56 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 83.91
1st Resistance Point 83.73
Last Price 83.56
1st Support Level 83.29
2nd Support Level 83.03

See More

52-Week High 94.19
Fibonacci 61.8% 85.83
Last Price 83.56
Fibonacci 50% 83.25
Fibonacci 38.2% 80.66
52-Week Low 72.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar